China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering
Rhea-AI Summary
China SXT Pharmaceuticals (NASDAQ: SXTC) entered into a definitive securities purchase agreement with certain institutional investors for a registered direct offering of 4,500,000 Units at $2.00 per Unit, each Unit consisting of one Class A ordinary share and one common warrant.
Each warrant will be immediately exercisable at $3.20 per share and will expire one year after issuance. According to China SXT Pharmaceuticals, expected aggregate gross proceeds are about $9 million before fees and expenses. The transaction is expected to close on or about July 24, 2025, subject to customary conditions, with Univest Securities acting as sole placement agent.
Positive
- $9 million expected gross proceeds before fees and expenses
- Warrants priced at $3.20, above the $2.00 Unit purchase price
Negative
- Issuance of 4,500,000 new Class A ordinary shares in the offering
- Additional potential share issuance from warrants exercisable for one year
News Explained
The company has entered a definitive agreement, but the offering remains subject to closing conditions; if completed, its
Market reaction after $9M registered direct offering: SXTC -83.53% in the Jul 23 session
In the Jul 23 session, SXTC declined 83.53%, reflecting a significant negative market reaction. Argus tracked a trough of -97.3% from its starting point during tracking. Our momentum scanner triggered 360 alerts that day, indicating exceptionally high trading interest and price volatility. Trading volume was exceptionally heavy at 68.0x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 09 | Registered offering | Negative | -87.9% | Prior $10 million registered direct offering drew a -87.92% 24-hour reaction. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The tag-specific record showed a negative reaction to the prior registered direct offering.
Key Terms
registered direct offering financial
common warrant financial
shelf registration statement regulatory
form f-3 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
TAIZHOU, China, July 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the “Company”), today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of an aggregate of 4,500,000 units (each, a “Unit”), consisting of one Class A ordinary share of the Company, no par value per share (each, a “Class A ordinary share”), and one common warrant (each, a “Warrant”), at a purchase price of
Each of the Warrants will have an exercise price of
Univest Securities, LLC is acting as the sole placement agent.
The registered direct offering is being made pursuant to a shelf registration statement on Form F-3 (File No. 333-291428) previously filed by the Company with the U.S. Securities and Exchange Commission (“SEC”) and became effective on December 1, 2025. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Univest Securities, LLC at info@univest.us, or by calling +1 (212) 343-8888.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Copies of the prospectus supplement relating to the registered direct offering, together with the accompanying base prospectus will be filed by the Company and, upon filing, can be obtained at the SEC's website at www.sec.gov.
About China SXT Pharmaceuticals Inc.
Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use. For more information, please visit www.sxtchina.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the U.S. Securities and Exchange Commission.
China SXT Pharmaceuticals Inc.
Feng Zhou, Chief Executive Officer
Email: fzhou@sxtchina.com
